AM-1714 (part of the
AM cannabinoid series) is a drug that acts as a reasonably selective
agonist of the peripheral
cannabinoid receptorCB2, with sub-nanomolar affinity and 490x selectivity over the related
CB1 receptor. In animal studies it has both
analgesic and anti-
allodynia effects. The 9-methoxy derivative AM-1710 has similar CB2 affinity but only 54x selectivity over CB1.[1][2]
^Khanolkar AD, Lu D, Ibrahim M, Duclos RI, Thakur GA, Malan TP, et al. (December 2007). "Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity". Journal of Medicinal Chemistry. 50 (26): 6493–500.
doi:
10.1021/jm070441u.
PMID18038967.
AM-1714 (part of the
AM cannabinoid series) is a drug that acts as a reasonably selective
agonist of the peripheral
cannabinoid receptorCB2, with sub-nanomolar affinity and 490x selectivity over the related
CB1 receptor. In animal studies it has both
analgesic and anti-
allodynia effects. The 9-methoxy derivative AM-1710 has similar CB2 affinity but only 54x selectivity over CB1.[1][2]
^Khanolkar AD, Lu D, Ibrahim M, Duclos RI, Thakur GA, Malan TP, et al. (December 2007). "Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity". Journal of Medicinal Chemistry. 50 (26): 6493–500.
doi:
10.1021/jm070441u.
PMID18038967.